Previous close | 90.07 |
Open | 90.07 |
Bid | 91.58 x 0 |
Ask | 92.40 x 0 |
Day's range | 90.07 - 90.07 |
52-week range | 66.01 - 92.79 |
Volume | |
Avg. volume | 1 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 16 July 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
A Relative Strength Rating upgrade for Morgan Stanley shows improving technical performance. Will it continue?
Morgan Stanley is to scrap the bonus cap for its London bankers in a post-Brexit shake-up that paves the way for multimillion-pound payouts to top performers.
(Bloomberg) -- Bicara Therapeutics is working with Morgan Stanley on a US initial public offering, people familiar with the situation said, as the market for first-time share sales is showing signs of normalizing. Most Read from BloombergJustice Department to Charge Boeing, Seeks Guilty Plea from PlanemakerBiden Asks Donors to Stay Following Disastrous DebateBiden's Defiance Has Democrats Fearing They'll Lose White HouseTrump as President or Private Citizen: Why Supreme Court’s Immunity Ruling I